Invasive fungal infections are silent killers, leading to more deaths annually than malaria, tuberculosis, or breast cancer.
Due to their rising incidence, high morbidity, and mortality rates, the WHO now recognises them as a global healthcare threat, with $8 Billion spent on antifungal drugs each year.
Early diagnosis of fungal infection is critical to effective treatment.
Diagnosis of fungal infection is challenging, partly because their symptoms are nonspecific or often overlap with bacterial or viral infections. Traditional culture-based diagnostic assays are characterised by long turnaround times and low specificity and sensitivity. This means fungal infections are often treated with an empiric approach, leading to patients being prescribed inappropriate treatments and increasing harmful resistance to antifungal drugs.
The development of laboratory-based and point-of-care tests can revolutionise the diagnostic workflow. The rapid and accurate identification of fungal infections in a culture-free workflow allows the initiation of species-oriented therapy as soon as possible and the creation of in-house test combinations suitable for different settings and diagnostics needs.
Real-time therapeutic decision making
Reduced drug resistance through appropriate prescribing
Implementing local testing programme
Compatible with existing laboratory equipment
Better resources utilisation
Improved patient care
